{"id":"placebo-for-diazoxide","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials. Any observed effects result from the placebo effect—a psychobiological phenomenon where patient expectations, conditioning, and the clinical context influence symptom perception and outcomes. In this case, it serves as a control comparator for diazoxide efficacy studies.","oneSentence":"A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:08.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials evaluating diazoxide efficacy"}]},"trialDetails":[{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT03540758","phase":"PHASE2","title":"Regulation of Endogenous Glucose Production by Central KATP Channels","status":"RECRUITING","sponsor":"Meredith Hawkins","startDate":"2018-08-01","conditions":"Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Glucose, High Blood","enrollment":100},{"nctId":"NCT03714373","phase":"PHASE3","title":"Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Prader-Willi Syndrome","enrollment":115},{"nctId":"NCT03440814","phase":"PHASE3","title":"A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Prader-Willi Syndrome","enrollment":127},{"nctId":"NCT03685773","phase":"PHASE2","title":"The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2019-04-21","conditions":"Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders","enrollment":""},{"nctId":"NCT02049385","phase":"PHASE1, PHASE2","title":"Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2014-01-03","conditions":"Depression","enrollment":10},{"nctId":"NCT00973271","phase":"PHASE3","title":"Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides","status":"WITHDRAWN","sponsor":"Essentialis, Inc.","startDate":"2011-03","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT01211847","phase":"PHASE2","title":"Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":44},{"nctId":"NCT00994149","phase":"PHASE2, PHASE3","title":"Diazoxide In the Management Of Hypoglycemic Neonates","status":"UNKNOWN","sponsor":"University of Saskatchewan","startDate":"2009-10","conditions":"Infant, Newborn, Diseases, Pregnancy in Diabetics, Infant, Diabetic Mother","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo (for Diazoxide)","genericName":"Placebo (for Diazoxide)","companyName":"Albert Einstein College of Medicine","companyId":"albert-einstein-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation. Used for Control arm in clinical trials evaluating diazoxide efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}